P.0421 Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – study design, rationale and current status

2021 ◽  
Vol 53 ◽  
pp. S306
Author(s):  
L.J. Mertens ◽  
M. Koslowski ◽  
F. Betzler ◽  
R. Evens ◽  
M. Gilles ◽  
...  
Keyword(s):  
Major Depression ◽  
Study Design ◽  
Current Status ◽  
Design Rationale ◽  
Efficacy And Safety ◽  
Treatment Resistant

Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression

2015 ◽  
pp. 1 ◽  
Author(s):  
Zubin Bhagwagar ◽  
Anne Torbeyns ◽  
Delphine Hennicken ◽  
Ming Zheng ◽  
Boadie W. Dunlop ◽  
...  
Keyword(s):  
Major Depression ◽  
Efficacy And Safety ◽  
Treatment Resistant

scholarly journals Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression

2018 ◽  
Vol 38 (6) ◽  
pp. 590-597 ◽  
Author(s):  
Sonia Vidal ◽  
Marianne Gex-Fabry ◽  
Victor Bancila ◽  
Giorgio Michalopoulos ◽  
Delphine Warrot ◽  
...  
Keyword(s):  
Major Depression ◽  
Intravenous Injection ◽  
Efficacy And Safety ◽  
Treatment Resistant

P.303 Augmenting strategies for treatment-resistant major depression using atypical antipsychotics

2021 ◽  
Vol 44 ◽  
pp. S40-S41
Author(s):  
I.A. Alexandru ◽  
I.E. Ghenoiu ◽  
R.E. Manolache ◽  
R.A. Lecu ◽  
M.I. Gionea
Keyword(s):  
Major Depression ◽  
Atypical Antipsychotics ◽  
Treatment Resistant

scholarly journals Anxiety as a risk factor for cardiovascular disease independent of depression: A narrative review of current status and conflicting findings

2021 ◽  
Vol 8 (1) ◽  
pp. 205510292098746
Author(s):  
Håvard R Karlsen ◽  
Florian Matejschek ◽  
Ingvild Saksvik-Lehouillier ◽  
Eva Langvik
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Study Design ◽  
Empirical Support ◽  
Narrative Review ◽  
Current Status ◽  
Depression And Anxiety ◽  
Evidential Support ◽  
Meta Analyses

The aim of this paper is to summarise and evaluate the empirical support for the association between anxiety and cardiovascular disease (CVD) and to address challenges related to method and study design. We review results from meta-analyses and more recent findings on the association of anxiety and the risk of CVD. Depression and anxiety are often listed as psychosocial risk markers of CVD, but the role of anxiety as a risk factor for CVD has not received the same evidential support as the effects of depression. Through a narrative review we identified six meta-analyses as well as 15 recent large studies of anxiety and CVD that we summarise. Some of the conflicting findings may be artefacts of study design or population the sample is drawn from. Researchers should take care to be population specific, measurement specific and outcome specific, and to control for comorbid depression.

A pilot study of hippocampal N-acetyl-aspartate in youth with treatment resistant major depression

2017 ◽  
Vol 207 ◽  
pp. 110-113 ◽  
Author(s):  
Danielle Lefebvre ◽  
Lisa Marie Langevin ◽  
Natalia Jaworska ◽  
Ashley D. Harris ◽  
R. Marc Lebel ◽  
...  
Keyword(s):  
Pilot Study ◽  
Major Depression ◽  
Treatment Resistant
Sign in / Sign up

Export Citation Format

Share Document